Digital Media briefs

Share this article:

Quintiles formed a Digital Patient unit, aimed at combining its online communities and digital expertise for clinical trial recruitment, among other things. Digital Patient will let firms recruit patients “by combing the digital universe” for patients seeking health information. That universe includes its patient communities (with 2.5 million registered users) and (165,000 registered users).

Pfizer tops pharma companies in social media spending and presence, said Cegedim Strategic Data in a study comparing spend in traditional media to that on Facebook and Twitter. The pharma giant was first in Twitter followers and third for Facebook Likes. Second-biggest spender Novartis ranks seventeenth in Facebook Likes and fifth in Twitter followers. Merck, the industry's third-largest promotional spender has the most Facebook pages, but is just fifteenth in Twitter followers.

Elsevier's The Lancet launched its first app for iPad, as did Wolters Kluwer's Oncology Times. named Dr. Tim Ringrose CEO. The physician social network, acquired by MDLinx owner M3 USA in August, named Ringrose to replace Richard ­Adams in that role.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?